Insider · CIK 0001713070
Shehnaaz Suliman
Files at RARE (Ultragenyx Pharmaceutical Inc.), TXG (10x Genomics, Inc.). First filing Sep 24, 2026, latest Sep 24, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TXG: 10x Genomics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | 10x Genomics, Inc. | $465k 5,723 shares | -19% | +612% from low0% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | TXG 10x Genomics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -292 | $78.20 | $23k | 29,223 | 18 d ago |
| Sep 22, 2026 | TXG 10x Genomics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -614 | $79.51 | $49k | 28,609 | 18 d ago |
| Sep 22, 2026 | TXG 10x Genomics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,325 | $80.82 | $107k | 27,284 | 18 d ago |
| Sep 22, 2026 | TXG 10x Genomics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -2,270 | $81.67 | $185k | 25,014 | 18 d ago |
| Sep 22, 2026 | TXG 10x Genomics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -1,222 | $82.28 | $101k | 23,792 | 18 d ago |
| Jun 3, 2025 | TXG 10x Genomics, Inc. | AGrant or award Class A Common Stock | +15,357 | $0.00 | $0 | 28,616 | Jun 5, 2025 |
| May 15, 2025 | RARE Ultragenyx Pharmaceutical Inc. | AGrant or award Common Stock | +5,740 | $0.00 | $0 | 25,940 | May 19, 2025 |
| May 15, 2025 | RARE Ultragenyx Pharmaceutical Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,787 | $0.00 | $0 | 10,787 | May 19, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.